Ye J.,Shanghai University |
Ye J.,Cpla No 98 Hospital |
Lv G.,Shanghai University |
Qian J.,Shanghai University |
And 3 more authors.
Journal of Neuro-Oncology | Year: 2016
Spinal World Health Organization (WHO) II and III meningiomas are relatively rare, and often associated with great clinical aggressiveness and poor overall survival. There are controversies over factors affecting the prognosis of this disease. The aim of this retrospective study was to evaluate factors that may affect the therapeutic outcome and prognosis of adult high-grade spinal meningiomas by reviewing the medical records of 25 patients who were surgically treated in our hospital between 2001 and 2014. Univariate and multivariate analyses were performed to identify prognostic variables relative to patient and tumor characteristics, and treatment modalities. All 25 patients (14 men and 11 women; mean age 46.6 ± 16.1 years) underwent surgical resection. Local recurrence was occurred in 13 (52.0 %) patients, and 10 (40.0 %) patients died during the follow-up periods. The 5-year recurrence rate was 60.0 % and the 5-year survival rate was 68.0 %. The results of statistical analysis suggested that Simpson resection grade and the number of involved segments were prognostic factors related to progression-free survival and that sex, age, preoperative Frankel score, the number of involved segments and WHO grade were closely correlated with survival. Furthermore, we confirmed that the number of involved segments was the major independent factor affecting recurrence of patients with adult spinal high-grade meningiomas, and that sex, age and WHO grade were prognostic factors affecting survival but not recurrence. © 2016 Springer Science+Business Media New York
PubMed | General Hospital of Guangzhou Military Command, Cpla No 425 Hospital, Jiaxing University and Cpla No 98 Hospital
Type: Journal Article | Journal: Journal of drug targeting | Year: 2016
The high transfection efficiency and enhanced therapeutic effect of drug delivery systems developed in recent years imply that ligand-decorated nanocarriers are potentially targeted vectors for breast cancer treatment. Thioaptamer (TA)-modified nanoparticles (NPs) designed in this study mainly consisted of ligand TA and dendritic polyamidoamine (PAMAM). Knowing that TA can bind to CD44-receptors in breast cancer, this study was intended to validate the safety and feasibility of systemic miRNA delivery to breast cancer cells by TA-PEG-PAMAM/miRNA (polyethylene glycol - PEG), testify its tumor targeting efficiency in vitro, and observe its biodistribution when it was administered systemically to a xenograft mouse model of breast cancer. The in vivo and ex vivo imaging results in human breast cancer tumor-bearing mice showed that TA-modification was able to enhance the accumulation of NPs in the breast cancer tumor. Our data showed that TA-NPs did not induce functional impairment to normal tissues and vital organs. TA-NPs may prove to be a safe and effective miRNA deliver system for breast cancer treatment, and could be widely used in pre-clinical and eventually clinical arenas of breast cancer treatment.
Zhao B.,Cpla No 98 Hospital |
Ye J.,Cpla No 98 Hospital |
Li B.,Cpla No 98 Hospital |
Ma Q.,Cpla No 98 Hospital |
And 2 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2013
Background: The polymorphism of XRCC3 Thr241Met has been indicated to be correlated with glioma susceptibility, but study results are still debatable. The present meta-analysis was performed to investigate the association between XRCC3 Thr241Met polymorphism and glioma. Methods: A total of 3754 glioma patients and 4849 controls from nine separate studies were involved. The pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) was assessed by the random-effects model. Results: The association between XRCC3 Thr241Met polymorphism and glioma was significant in the recessive model (OR = 1.36; 95% CI, 1.02-1.82; P = 0.03). In a stratified analysis by the ethnicity, significantly increased risk was detected in Asians (OR = 1.93; 95% CI, 1.18-3.17; P = 0.009). Conclusions: In conclusion, XRCC3 Thr241Met polymorphism was implied to be associated with increased glioma risk. More studies are needed to validate this result.